

Hensin Tsao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3450788/publications.pdf>

Version: 2024-02-01

114
papers

7,529
citations

76294

40
h-index

53190

85
g-index

116
all docs

116
docs citations

116
times ranked

9524
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Cutaneous Melanoma. <i>New England Journal of Medicine</i> , 2004, 351, 998-1012.	13.9	735
2	Melanoma: from mutations to medicine. <i>Genes and Development</i> , 2012, 26, 1131-1155.	2.7	415
3	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. <i>Nature</i> , 2011, 480, 99-103.	13.7	413
4	Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma. <i>Journal of Investigative Dermatology</i> , 2004, 122, 337-341.	0.3	411
5	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 208-250.	0.6	400
6	High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. <i>Cancer Research</i> , 2006, 66, 9818-9828.	0.4	373
7	The Transformation Rate of Moles (Melanocytic Nevi) Into Cutaneous Melanoma. <i>Archives of Dermatology</i> , 2003, 139, 282.	1.7	282
8	Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. <i>Oncogene</i> , 1998, 16, 3397-3402.	2.6	224
9	Cutaneous Melanomas Associated With Nevi. <i>Archives of Dermatology</i> , 2003, 139, 1620.	1.7	224
10	Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. <i>Human Mutation</i> , 2007, 28, 578-588.	1.1	222
11	Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. <i>Cancer Research</i> , 2000, 60, 1800-4.	0.4	185
12	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1328-1341.	3.0	164
13	Hereditary melanoma: Update on syndromes and management. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 395-407.	0.6	158
14	Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2575-2595.	0.3	157
15	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	0.8	148
16	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. <i>Cancer</i> , 1997, 79, 2361-2370.	2.0	142
17	Genetics of melanocytic nevi. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 661-672.	1.5	135
18	Gender Disparity and Mutation Burden in Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv221.	3.0	114

#	ARTICLE	IF	CITATIONS
19	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. <i>Cancer Discovery</i> , 2015, 5, 274-287.	7.7	107
20	PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 865-872.	0.6	103
21	Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 4026-4036.	3.2	96
22	Somatic driver mutations in melanoma. <i>Cancer</i> , 2017, 123, 2104-2117.	2.0	96
23	Expression Profiling of UVB Response in Melanocytes Identifies a Set of p53-Target Genes. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2490-2506.	0.3	86
24	Genotypic and Phenotypic Features of BAP1 Cancer Syndrome. <i>JAMA Dermatology</i> , 2017, 153, 999.	2.0	86
25	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype. <i>Cancer Discovery</i> , 2015, 5, 264-273.	7.7	82
26	A recurrent germline <i>BAP1</i> mutation and extension of the <i>BAP1</i> tumor predisposition spectrum to include basal cell carcinoma. <i>Clinical Genetics</i> , 2015, 88, 267-272.	1.0	81
27	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	1.5	77
28	MITF Modulates Therapeutic Resistance through EGFR Signaling. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1863-1872.	0.3	76
29	Outcome of patients with de novo versus nevus-associated melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 54-58.	0.6	71
30	KIT and Melanoma: Biological Insights and Clinical Implications. <i>Yonsei Medical Journal</i> , 2020, 61, 562.	0.9	67
31	p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. <i>Journal of Investigative Dermatology</i> , 2012, 132, 356-364.	0.3	66
32	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , 2019, 27, 3573-3586.e7.	2.9	66
33	Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 91, 874-880.	2.0	61
34	Hereditary melanoma: Update on syndromes and management. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 411-420.	0.6	60
35	Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. <i>Cancer Research</i> , 1998, 58, 109-13.	0.4	56
36	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	3.2	53

#	ARTICLE	IF	CITATIONS
37	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1002-1011.	0.3	51
38	Burden of unique and low prevalence somatic mutations correlates with cancer survival. <i>Scientific Reports</i> , 2019, 9, 4848.	1.6	49
39	High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1582-1590.	0.3	46
40	The first 30 years of the American Academy of Dermatology skin cancer screening program: 1985-2014. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 884-891.e3.	0.6	46
41	Early Detection of Asymptomatic Pulmonary Melanoma Metastases by Routine Chest Radiographs Is Not Associated With Improved Survival. <i>Archives of Dermatology</i> , 2004, 140, 67-70.	1.7	45
42	Hypopigmentation Associated With an Adenovirus-Mediated gp100/MART-1 Transduced Dendritic Cell Vaccine for Metastatic Melanoma. <i>Archives of Dermatology</i> , 2002, 138, 799-802.	1.7	42
43	Melanoma: Clinical Features and Genomic Insights. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a015388-a015388.	2.9	42
44	Hypoxia and HIF-1 α Regulate Collagen Production in Keloids. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2157-2165.	0.3	39
45	A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. <i>Archives of Dermatology</i> , 2001, 137, 325-30.	1.7	39
46	BRCA1-associated protein (BAP1) inactivated melanocytic tumors. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 965-972.	0.7	38
47	Mutational and expression analysis of the p73 gene in melanoma cell lines. <i>Cancer Research</i> , 1999, 59, 172-4.	0.4	34
48	Vemurafenib Synergizes with Nutlin-3 to Deplete Survivin and Suppresses Melanoma Viability and Tumor Growth. <i>Clinical Cancer Research</i> , 2013, 19, 4383-4391.	3.2	33
49	In vivo coherent Raman imaging of the melanomagenesis-associated pigment pheomelanin. <i>Scientific Reports</i> , 2016, 6, 37986.	1.6	33
50	Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	32
51	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. <i>Cancer</i> , 1997, 79, 2361-70.	2.0	32
52	The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1071-1076.	0.6	31
53	BAP1 Has a Survival Role in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1089-1097.	0.3	31
54	Cutaneous melanoma in women. <i>International Journal of Women's Dermatology</i> , 2017, 3, S11-S15.	1.1	29

#	ARTICLE	IF	CITATIONS
55	Contrasting features of childhood and adolescent melanomas. <i>Pediatric Dermatology</i> , 2018, 35, 354-360.	0.5	26
56	Melanocytes Are Selectively Vulnerable to UVA-Mediated Bystander Oxidative Signaling. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1083-1090.	0.3	24
57	Melanoma Treatment Update. <i>Dermatologic Clinics</i> , 2005, 23, 323-333.	1.0	23
58	Use of Targeted Next-Generation Sequencing to Identify Activating Hot Spot Mutations in Cherry Angiomas. <i>JAMA Dermatology</i> , 2019, 155, 211.	2.0	22
59	Epidermal, Sebaceous, and Melanocytic Nevoid Proliferations Are Spectrums of Mosaic RASopathies. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2493-2496.	0.3	21
60	Clinical spectrum of cutaneous melanoma morphology. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 178-188.e3.	0.6	21
61	Effect of the COVID-19 Pandemic on Delayed Skin Cancer Services. <i>Dermatologic Clinics</i> , 2021, 39, 627-637.	1.0	21
62	Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline <i>BAP1</i> Mutation. <i>JAMA Dermatology</i> , 2015, 151, 1235.	2.0	20
63	Cancer risks associated with the germline <i>MITF</i> (E318K) variant. <i>Scientific Reports</i> , 2020, 10, 17051.	1.6	20
64	Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 60-67.	1.6	20
65	Germline <i>ATM</i> variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum consortia. <i>Genetics in Medicine</i> , 2021, 23, 2087-2095.	1.1	19
66	Visual Inspection and the US Preventive Services Task Force Recommendation on Skin Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 398.	3.8	18
67	Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines. , 1997, 72, 337-339.		16
68	Classifying Melanoma by TERT Promoter Mutational Status. <i>Journal of Investigative Dermatology</i> , 2020, 140, 390-394.e1.	0.3	16
69	A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 55-61.	0.6	15
70	Cutaneous melanoma in women. <i>International Journal of Women's Dermatology</i> , 2015, 1, 21-25.	1.1	12
71	Targeted Therapies in Melanoma: Translational Research at Its Finest. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1929-1933.	0.3	12
72	Recent Advances in Melanoma and Melanocyte Biology. <i>Journal of Investigative Dermatology</i> , 2017, 137, 557-560.	0.3	12

#	ARTICLE	IF	CITATIONS
73	Melanoma genomics: a state-of-the-art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281.	1.4	12
74	Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma. Oncogene, 2019, 38, 3504-3520.	2.6	11
75	Update on familial cancer syndromes and the skin. Journal of the American Academy of Dermatology, 2000, 42, 939-69; quiz 970-2.	0.6	11
76	Defining Clonal Color in Fluorescent Multi-Clonal Tracking. Scientific Reports, 2016, 6, 24303.	1.6	10
77	Beta-catenin causes fibrotic changes in the extracellular matrix via upregulation of collagen I transcription. British Journal of Dermatology, 2017, 177, 312-315.	1.4	10
78	Selective uveal melanoma inhibition with calcium channel blockade. International Journal of Oncology, 2019, 55, 1090-1096.	1.4	10
79	Case 7-2004. New England Journal of Medicine, 2004, 350, 924-932.	13.9	9
80	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465.	2.2	9
81	A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel, Switzerland), 2019, 6, 255-259.	0.7	9
82	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. Journal of Investigative Dermatology, 2021, 141, 1317-1324.e1.	0.3	9
83	A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biology and Therapy, 2016, 17, 778-784.	1.5	8
84	Surgical delay and mortality for primary cutaneous melanoma. Journal of the American Academy of Dermatology, 2021, 84, 1089-1091.	0.6	8
85	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. Journal of Investigative Dermatology, 2021, 141, 2018-2027.e4.	0.3	8
86	Factors associated with suspected nonmelanoma skin cancers, dysplastic nevus, and cutaneous melanoma among first-time SpotMe screening program participants during 2009-2010. Journal of the American Academy of Dermatology, 2023, 88, 60-70.	0.6	6
87	Consensus, Controversy, and Conversations About Gene Expression Profiling in Melanoma. JAMA Dermatology, 2020, 156, 949.	2.0	6
88	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. American Journal of Cancer Research, 2017, 7, 134-138.	1.4	6
89	Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. BMC Cancer, 2021, 21, 371.	1.1	5
90	Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer, 1997, 79, 2361-2370.	2.0	5

#	ARTICLE	IF	CITATIONS
91	Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 863-870.	0.6	4
92	New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi—Highlighting the Keratinocyte-Melanocyte Relationship. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1933-1935.	0.3	4
93	Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. <i>European Journal of Human Genetics</i> , 2019, 27, 824-828.	1.4	4
94	The spectrum of morphologic patterns of nodular melanoma: a study of the International Dermoscopy Society. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e762-e765.	1.3	4
95	Recognition, Staging, and Management of Melanoma. <i>Medical Clinics of North America</i> , 2021, 105, 643-661.	1.1	4
96	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. <i>Melanoma Management</i> , 2015, 2, 133-147.	0.1	3
97	Cutaneous Presentation of Mesothelioma With a Sarcomatoid Transformation. <i>American Journal of Dermatopathology</i> , 2018, 40, 378-382.	0.3	3
98	Number needed to screen for presumptive screening diagnoses among first-time SPOTme screening participants (1992-2010). <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 233-234.	0.6	3
99	Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1413-1424.e6.	0.3	3
100	Melanoma-associated naevi: precursors or coincidence?. <i>British Journal of Dermatology</i> , 2015, 173, 633-634.	1.4	2
101	Epidemiology of Melanoma. , 2017, , 591-611.		2
102	The SNPs of RAF. <i>Journal of Investigative Dermatology</i> , 2005, 125, xiv-xv.	0.3	1
103	Unsupervised Phenotype-Based Clustering of Clinicopathologic Features in Cutaneous Melanoma. <i>JID Innovations</i> , 2021, 1, 100047.	1.2	1
104	Epithelioid Sarcoma Presenting as a Benign Foot Ulcer. <i>Journal of Cutaneous Medicine and Surgery</i> , 1997, 1, 232-234.	0.6	0
105	Case 30-2010. <i>New England Journal of Medicine</i> , 2010, 363, 1352-1360.	13.9	0
106	Opening the melanoma black box. <i>British Journal of Dermatology</i> , 2014, 170, 9-10.	1.4	0
107	Concerns About Presence of a Wild-Type <i>BAP1</i> Allele in Absence of Nuclear Protein Expression—Reply. <i>JAMA Dermatology</i> , 2015, 151, 1266.	2.0	0
108	Reply to: “The ABCDs of melanoma” A complicated morphologic message not intended for the general public. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e61.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Reply to: "The absence of multiple atypical nevi in germline CDKN2A mutations". Journal of the American Academy of Dermatology, 2016, 75, e159.	0.6	0
110	Introduction to JID's Landmarks in the Molecular Revolution. Journal of Investigative Dermatology, 2017, 137, 996.	0.3	0
111	A geographically based cross-sectional analysis of SPOT me skin cancer screening data. Journal of the American Academy of Dermatology, 2021, 84, 809-810.e3.	0.6	0
112	Melanoma medicine in the new millennium. British Journal of Dermatology, 2021, 185, 239-240.	1.4	0
113	Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma. , 2021, , .		0
114	American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Targets of genetic injury in cutaneous melanoma. Journal of the American Academy of Dermatology, 1999, 41, 459-61.	0.6	0